Merck & Co., Inc.: PharmaVitae Report
ReportsnReports.com adds DataMoniter Market Research Report “Merck & Co., Inc.: PharmaVitae Report’’ to its store.
This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Merck & Co.'s strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Although overshadowed by recent M&A activity, a period of impressive R&D productivity in which Merck launched a number of new products (e.g. Janunvia, Isentress) was key to the company overcoming sizeable challenges which included the withdrawal of Vioxx and patent expiries of Zocor, Fosamax and Cozaar/Hyzaar.
Your key questions answered
- Benchmark Merck & Co.'s performance against key rivals in the prescription pharmaceutical sector
- Identify the near-term and long-term impact of the Schering-Plough acquisiton on Merck's commercial and financial outlook
- Analyse whether Merck's diversified business model and pipeline can cope with the impact of blockbuster patent expiries
Table Of Contents
Executive Summary
Key findings
Merck prescription pharma sales outlook
Merck financial outlook
Key developments
Recent developments
Upcoming developments
SWOT analysis
[Missing title]
Weaknesses
Opportunities
Threats
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Company Introduction
Sales Analysis
Financial Analysis
Product Analysis
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Strategic insight
New launches pivotal to Merck’s outlook – strengthened by Schering-Plough pipeline
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Acquisitions
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004–10
Operating costs and profit analysis
Operating costs and profit analysis
Operating cost ratio and profit margin analysis, 2004–10
PRODUCT ANALYSIS
Overview
Sitagliptin franchise
Remicade
Ezetimibe franchise
Singulair
ProQuad/MMRII/Varivax
Isentress
Cozaar/Hyzaar
Victrelis
Merck pipeline overview
APPENDIX
Abbreviations
Exchange rates
Latest Market Research Reports:
Executive Summary
Key findings
Merck prescription pharma sales outlook
Merck financial outlook
Key developments
Recent developments
Upcoming developments
SWOT analysis
[Missing title]
Weaknesses
Opportunities
Threats
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Company Introduction
Sales Analysis
Financial Analysis
Product Analysis
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Strategic insight
New launches pivotal to Merck’s outlook – strengthened by Schering-Plough pipeline
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Acquisitions
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004–10
Operating costs and profit analysis
Operating costs and profit analysis
Operating cost ratio and profit margin analysis, 2004–10
PRODUCT ANALYSIS
Overview
Sitagliptin franchise
Remicade
Ezetimibe franchise
Singulair
ProQuad/MMRII/Varivax
Isentress
Cozaar/Hyzaar
Victrelis
Merck pipeline overview
APPENDIX
Abbreviations
Exchange rates
Latest Market Research Reports:
- Radiation Detection Materials Markets – 2011
- Planned LNG Terminals Market – Global Analysis, Competitive Landscape and Capacity Forecasts to 2016
- Printed Battery Markets – 2011
- Planned Oil and Gas Pipelines – Global Market Analysis, Competitive Landscape and Major Projects to 2015
- World Rare Earths
About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Market Research Blog
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Market Research Blog
